Reference number : GC-2017-Q3-00450, amendment number : , agreement type : G, recipient legal name : Green, Sheldon (The University of British Columbia), recipient country : CA, recipient province : nan, recipient city : British Columbia|Colombie-Britannique, recipient postal code : nan, program name english : Engage Grants for universities, program name french : Subventions d'engagement partenarial pour les universités, program purpose english : Cardiovascular disease is the leading cause of death in the world. According to the American Heart_x000D_
Association, more than 85 million Americans suffer from cardiovascular disease with the total treatment_x000D_
spending exceeding $320B in 2011 and expected to reach $1,208B in 2030. Aortic pathologies such as_x000D_
dissection and aneurysm represent a particularly emergent class of cardiovascular diseases. Open surgical_x000D_
procedure is the current gold standard for treating thoracic aortic dissection. However, the stent graft_x000D_
implantation is one of the potential alternatives for treating patients at high risk for an open surgical procedure._x000D_
Various hemodynamic parameters are suspected to be major mechanical factors related to the genesis and_x000D_
aneurysm growth._x000D_
Vivitro Labs Inc. is an industry-leading cardiovascular test equipment and related laboratory testing company._x000D_
Services include the assessment of hydrodynamic performance of cardio devices which are used for submission_x000D_
with regulatory bodies such as the FDA. ViVitro's pulse duplicator is the most widely used heart simulator in_x000D_
the world. The company's problem is to broaden the suitability of the heart simulator to simulate a descending_x000D_
aortic aneurysm before and after treatment by the stent graft implantation. The objective of this study is to_x000D_
investigate the suitability of the ViVitro's simulator for aortic aneurysm before and after stent graft_x000D_
implantation., program purpose french : Cardiovascular disease is the leading cause of death in the world. According to the American Heart_x000D_
Association, more than 85 million Americans suffer from cardiovascular disease with the total treatment_x000D_
spending exceeding $320B in 2011 and expected to reach $1,208B in 2030. Aortic pathologies such as_x000D_
dissection and aneurysm represent a particularly emergent class of cardiovascular diseases. Open surgical_x000D_
procedure is the current gold standard for treating thoracic aortic dissection. However, the stent graft_x000D_
implantation is one of the potential alternatives for treating patients at high risk for an open surgical procedure._x000D_
Various hemodynamic parameters are suspected to be major mechanical factors related to the genesis and_x000D_
aneurysm growth._x000D_
Vivitro Labs Inc. is an industry-leading cardiovascular test equipment and related laboratory testing company._x000D_
Services include the assessment of hydrodynamic performance of cardio devices which are used for submission_x000D_
with regulatory bodies such as the FDA. ViVitro's pulse duplicator is the most widely used heart simulator in_x000D_
the world. The company's problem is to broaden the suitability of the heart simulator to simulate a descending_x000D_
aortic aneurysm before and after treatment by the stent graft implantation. The objective of this study is to_x000D_
investigate the suitability of the ViVitro's simulator for aortic aneurysm before and after stent graft_x000D_
implantation., agreement title english : Endovascular simulator for aortic aneurysms, agreement title french : Endovascular simulator for aortic aneurysms, agreement number : EGP, agreement value : 25000.0, agreement start date : 2017-12-13, agreement end date : nan, description english : nan, description french : nan, expected results english : nan, expected results french : nan, additional information english : Grant or Award spanning more than one fiscal year (2017-2018 to 2018-2019)., additional information french : Subvention ou bourse octroyée s'appliquant à plus d'un exercice financier (2017-2018 à 2018-2019)., owner organization : nserc-crsng, owner organization title : Natural Sciences and Engineering Research Council of Canada | Conseil de recherches en sciences naturelles et en génie du Canada